Abstract
The tetracycline analogs minocycline and doxycycline are inhibitors of metalloproteinases (MMPs) and have been shown to inhibit angiogenesis in vivo. To further study the mechanism of action of these compounds we tested them in an in vitro model of angiogenesis: aortic sprouting in fibrin gels. Angiogenesis was quantitated in this system by a unique application of planar morphometry. Both compounds were found to potently inhibit angiogenesis in this model. To further characterize the activity of these compounds against MMPs, we determined the IC50s of both compounds against representatives of three classes of metalloproteinases: fibroblast collagenase, stromelysin, and gelatinase A. Doxycycline was found to inhibit collagenase, gelatinase A and stromelysin with IC50s of 452 μM, 56 μM and 32 μM, respectively. Minocycline was found to inhibit only stromelysin in the micromolar range with an IC50 of 290 μM. Since these results suggest that these compounds may not have been inhibiting in vitro angiogenesis by an MMP-dependent mechanism, we decided to test the effects of the potent MMP inhibitor BB-94. This compound failed to inhibit aortic sprouting in fibrin gels, thus strongly suggesting that both doxycycline and minocycline act by an MMP-independent mechanism. These results have implications for the mechanism of action of tetracycline analogs, particularly where they are being considered for the treatment of disorders of extracellular matrix degradation including periodontal disease, arthritis, and tumor angiogenesis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Ausprunk DH, Folkman J (1977) Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14: 53–65
Burns FR, Stack MS, Gray RD, Paterson CA (1989) Inhibition of purified collagenase from alkali-burned rabbit corneas. Invest Ophthalmol Vis Sci 30(7): 1569–1575
Campion C, Davidson AH, Dickens JP, Crimmin MJ (1990) Hydroxamic acid based collagenase inhibitors. British Biotechnology Patent WO 90/05719
Cawston, TE, Barrett AJ (1979) A rapid and reproducible assay for collagenase using [1-14C]acetylated collagen. Anal Biochem 99: 340–345
Davies B, Brown PD, East N, Crimmen MJ, Balkwill FR (1993) A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53: 2787–2791
DeClerck Y, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM (1992) Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 52: 701–708
Dixit SN, Mainardi CL, Seyer JM, Kang AH (1979) Covalent structure of collagen: amino acid sequence of a2-CB5 of chick skin collagen containing the animal collagenase cleavage site. Biochemistry 18: 5416–5422
Fisher C, Gilbertson-Beadling S, Powers EA, Petzold G, Poorman R, Mitchell MA (1994) Interstitial collagenase is required for angiogenesis in vitro. Dev Biol 162: 499–510
Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 267(16): 10931–10934
Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R, Ramamurthy NS (1983) Minocycline reduces gingival collagenolytic activity during diabetes: preliminary observations and a proposed new mechanism of action. J Periodontal Res 18: 516–526
Golub, LM, Ramamurthy NS, McNamara TS, Gomes B, Wolff M, Ciancio S, Schneir M, Perry H (1984) Tetracyclines inhibit tissue collagenase activity: a new mechanism in the treatment of periodonal disease. J Periodontal Res 19: 651–655
Greenwald RA, Moak SA, Ramamurthy NS, Golub LM (1992) Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage. J Rheumatol 19 (6): 927–938
Guerin C, Laterra J, Masnyk T, Golub LM, Brem H (1992) Selective endothelial growth inhibition by tetracyclines that inhibit collagenase. Biochem Biophys Res Commun 188 (2): 740–745
Ingman T, Sorsa T, Suomalainen K, Halinen S, Lindy O, Lauhio H, Saari H, Konttinen YT, Golub LM (1993) Tetracycline inhibition and the cellular source of collagenase in gingival crevicular fluid in different periodontal diseases. A review article. J Periodontol 64 (2): 82–88
Khokha R (1994) Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor metalloproteinases-1. J Natl Cancer Inst 86(4): 299–304
Marcy AI, Eiberger LL, Harrison R, Chan HK, Hutchinson NI, Hagmann WK, Cameron PM, Boulton DA, Hermes JD (1991) Human fibroblast stromelysin catalytic domain: expression, purification, and characterization of a C-terminally truncated form. Biochemistry 30: 6476–6483
Matrisian LM (1990) Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6(4): 121–125
Mignatti P, Tsuboi R, Robbins E, and Rifkin DB (1989) In-vitro angiogenesis on the human amniotic membrane: requirement of basic fibroblast growth factor-induced proteinases. J Cell Biol 108 (2): 671–682
Miller EJ, Harris ED, Chung E, Finch J, McCroskery PA, Butler WT (1976) Cleavage of type II and III collagens with mammalian collagenase: site of cleavage and primary structure at the NH2-terminal portion of the smaller fragment released from both collagens. Biochemistry 15: 787–792
Montesano D, Vassalli J-D, Baird A, Guillemin R, Orci L (1986) Basic fibroblast gowth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA 83: 7297–7301
Mørk A, Geisler A (1993) Effects of minocycline on accumulation of cyclic AMP in cerebral cortex of rat. A comparison with lithium. Neuropharmacology 32(8): 793–798
Moscatelli D, Rifkin DB (1988) Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. Biochim Biophys Acta 948: 67–85
Neuvonen PJ (1976) Interactions with the absorption of tetracyclines. Drugs 11: 45–54
Nicosia RF, Madri JA (1987) The microvascular extracellular matrix: developmental changes during angiogenesis in the aortic ring-plasma clot model. Am J Pathol 128: 78–90
Pepper MS, Belin D, Montesano R, Orci L, Vassalli J-D (1990) Transforming growth factor beta 1 modulates basic fibroblastinduced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol 111: 743–755
Sotomayor EA, Teicher BA, Schwartz GN, Holden SA, Menon K, Herman TS, Frei E (1992) Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo. Cancer Chemother Pharmacol 30 (5): 377–384
Stetler-Stevenson WG (1990) Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 9 (4): 289–303
Suomalainen K, Sorsa T, Golub LM, Ramamurthy N, Lee HM, Uitto VJ, Saari H, Konttinen YT (1992) Specificity of the anticollagenase action of tetracyclines: relevance to their anti-in flammatory potential. Antimicrob Agents Chemother 36 (1): 227–229
Suomalainen K, Halinen S, Ingman T, Lindy O, Saari H, Konttinen YT, Golub LM, Sorsa T (1992) Tetracycline inhibition identifies the cellular sources of collagenase in gingival crevicular fluid in different forms of periodontal diseases. Drugs Exp Clin Res 18 (3): 99–104
Tamargo RJ, Bok RA, Brem H (1991) Angiogenesis inhibition by minocycline. Cancer Res 51 (2): 672–675
Teicher BA, Sotomayor EA, Huang ZD (1992) Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52 (23): 6702–6704
Wilhelm SM, Collier IE, Kronberger A, Eisen AZ, Marmer BL, Grant GA, Bauer EA, Goldberg GI (1987) Human skin fibroblast stromelysin: structure, glycosylation, substrate specificity, and differential expression in normal and tumorigenic cells. Proc Natl Acad Sci USA 84 (19): 6725–6729
Zucker S, Lysik RM, Ramamurthy NS, Golub LM, Wieman JM, Wilkie DP (1985) Diversity of melanoma plasma membrane proteinases: inhibition of collagenolytic and cytolytic activities by minocycline. J Natl Cancer Inst 75 (3): 517–525
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gilbertson-Beadling, S., Powers, E.A., Stamp-Cole, M. et al. The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism. Cancer Chemother. Pharmacol. 36, 418–424 (1995). https://doi.org/10.1007/BF00686191
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686191